発表概要：SDT fattyラットを用いたGLP-1作動薬評価を通じ、CKM志向型創薬への応用可能性を検討

Abstract No：WCN26-AB-5615
発表日：2026年3月30日（月）
ポスターボード：P121
場所：Exhibition Hall B（1F）
セッション時間： 17:00–18:00

Key Word（キーワード）：
Cardiovascular–Kidney–Metabolic, Semaglutide, GLP-1 receptor agonist, SDT fatty rat

François Briand^１、Guillaume Bourdier^２、Estelle Grasset^１、Rana Assaly^２Caroline Dubroca^２、Masami Shinohara^３、Thierry Sulpice^１、２ 

^１Physiogenex, 280 rue de l’Hers, 31750, Escalquens, France
^２Cardiomedex, 280 rue de l’Hers, 31750, Escalquens, France
^３CLEA Japan, Inc., 1–2–7 Higashiyama, Meguro-ku, Tokyo 153-8533, Japan

For more details, please click here (Google Search)

• World Congress of Nephrology 2026
• Monday, March 30, 2026 | 17:00–18:00 Pacifico Yokohama, Japan

Related CLEA Japan product: SDT fatty/Jcl

For the animal model, please click here ▼

: https://www.clea-japan.com/en/products/diabetes/item_a0150

: https://www.clea-japan.com/products/diabetes/item_a0150

Inquiry（お問い合わせ）

If you have any questions, please feel free to contact us.